Related Experiment Videos
Therapeutic vaccination against HIV
1Dept of Microbiology and Tumorbiology, Karolinska Institute, Swedish Institute for Infectious Disease Control, 171 82 Stockholm, Sweden. Britta.Wahren@smi.ki.se
Expert Review of Vaccines
|August 3, 2004
Summary
Therapeutic vaccines show promise for HIV by improving survival and delaying viral failure, especially when combined with antiviral therapy. Early intervention is crucial for effective immune responses against neglected epitopes in immunocompromised individuals.
Area of Science:
- Immunology
- Virology
- Vaccinology
Background:
- The challenge in HIV immunotherapy is to boost antiviral responses in immunocompromised hosts.
- Developing vaccines that target neglected epitopes is essential for effective treatment.
Purpose of the Study:
- To review therapeutic vaccination strategies for Human Immunodeficiency Virus (HIV).
- To assess the efficacy of using structural and regulatory genes and proteins for therapeutic vaccination.
Main Methods:
- Review of existing literature on therapeutic HIV vaccination.
- Analysis of clinical results from studies using structural and regulatory HIV genes/proteins.
Main Results:
- Promising short-term survival improvements observed without antiretroviral therapy.
- Combined immunization and antiviral therapy prolonged time to virological failure.
- Need for adjuvants and modulators to activate natural killer and T-cells identified.
Conclusions:
- Therapeutic HIV vaccination can enhance antiviral responses and delay disease progression.
- Early vaccine administration is critical to leverage available T-helper and memory cell populations.
- Adjuvants and immune modulators are necessary to optimize vaccine efficacy.